Trial results

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 on ClinicalTrials.gov · last registry update 2026-08-21

Recruiting now, toward 350 participants. Due to report April 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

350

Started

2025-06-26

Primary completion

2028-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction

Conditions studied

Ulcerative Colitis · Obesity or Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.